Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc. is advancing its clinical-stage pipeline, particularly with its lead candidate icovamenib, which has shown significant reductions in HbA1c levels in Type 2 diabetes patients over 52 weeks, indicating potential for long-term disease modification. The company is also progressing BMF-650, an oral GLP-1 receptor agonist that demonstrated promising preclinical weight reduction and glycemic control results, signaling a strong therapeutic potential for obesity and diabetes management. Furthermore, Biomea Fusion has made strides in capitalizing its pipeline through a proposed equity and warrant offering, while reducing its net loss significantly from $32.8 million in Q3 2024 to $16.4 million in Q3 2025, underscoring improved financial health.

Bears say

Biomea Fusion Inc has shown a significant reduction in research and development (R&D) expenses, dropping from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, which may suggest operational inefficiencies or reduced investment in critical areas for product development. General and administrative (G&A) expenses also declined from $6.8 million to $4.2 million, further indicating cost-cutting measures that may not align with growth expectations. Additionally, the company's price target was lowered due to changes in the share count, reflecting a potentially negative adjustment in market sentiment regarding the company's valuation.

BMEA has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 7 analysts, BMEA has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.